The Triglyceride Glucose (TyG) index is a new and sensitive marker of Insulin Resistance (IR). Its relationship with a 10-year cardiovascular risk (CVD) in hypertensives in Nigeria is currently unknown. This was a cross-sectional study involving 1,430 adult Nigerians with hypertension. The TyG index of subjects was divided into quartiles (Q1-Q4), and its association with 10-year CVD risk using Framingham 10-year Cardiovascular Risk Score was explored. The mean age of the study population was 55.8 ± 13.9 years with a male preponderance of 54.1%. The mean TyG index was 8.72 ± 0.6 with a significantly higher value in males (8.77 ± 0.6 vs 8.67 ± 0.5; p = 0.001). This trend was consistent across all age groups. The prevalence of elevated TyG index was 51.9% and 44.7% in males and females respectively. Using ROC the cut-offs that predicted moderate to high CVD risk were 8.85 (0.69(0.57-0.80; 95% CI; p = 0.001) and 8.74 (0.688 (0.59-0.78; 95% CI; p = 0.001) for males and females respectively. After adjustment for well-known risk factors, an elevated TyG index was associated with an increased 10-year CVD risk in females only. The TyG index is associated with an increased 10-year cardiovascular risk especially in females and a value of at least 8.7 is reasonably accurate to predict a 10-year CVD risk in Nigerians with hypertension.

Hypertension remains the leading modifiable risk factor for global morbidity and mortality, disproportionately affecting low- and middle-income countries (

Background: Aldosterone synthase inhibitors (ASIs) have emerged as a mechanistically targeted strategy for resistant and uncontrolled hypertension; however, no head-to-head trials exist, and comparative efficacy and safety remain uncertain. We compared their efficacy and safety using network and pairwise meta-analysis of randomized trials. Methods: This systematic review and meta-analysis adhered to the PRISMA guidelines. PubMed/MEDLINE, Scopus, Embase, ClinicalTrials.gov, and Cochrane Library were searched from inception to January 14, 2026, for randomized trials evaluating ASIs versus placebo or standard care. A frequentist random-effects network meta-analysis assessed systolic (SBP) and diastolic blood pressure (DBP). Dichotomous safety outcomes were pooled using Hartung–Knapp random-effects models. Network consistency was evaluated using design-by-treatment interaction modeling. Prespecified subgroup analyses stratified outcomes by hypertension phenotype (resistant vs uncontrolled). Results: Across 7 RCTs (n = 2,828), all ASIs significantly reduced SBP versus placebo: baxdrostat −8.63 mmHg (95% CI −10.84 to −6.42), lorundrostat −7.47 mmHg (95% CI −9.54 to −5.40), and LCI699/osilodrostat −5.63 mmHg (95% CI −9.15 to −2.12), with no significant indirect differences between agents. In resistant hypertension, lorundrostat (−9.00 mmHg; 95% CI −13.19 to −4.81) and baxdrostat (−8.77 mmHg; 95% CI −10.50 to −7.05) demonstrated pronounced reductions. In uncontrolled hypertension, LCI699/osilodrostat showed the largest point estimate (−10.55 mmHg; 95% CI −16.49 to −4.61), though this derives from a single early-phase trial and requires cautious interpretation. DBP reductions were significant for baxdrostat (−3.23 mmHg; 95% CI −4.73 to −1.73) and lorundrostat (−3.60 mmHg; 95% CI −5.43 to −1.77). Hypotension (RR 2.67), hyperkalemia (RR 7.94), and hyponatremia (RR 2.07) were significantly increased; serious adverse events, discontinuation, and network inconsistency were not detected. Conclusions: ASIs provide clinically meaningful BP reduction across both hypertension phenotypes; however, short-term use is associated with hypotension and electrolyte disturbances, necessitating careful monitoring. Phenotype-specific efficacy and long-term safety require validation in outcome-driven trials. Systematic Review Registration: PROSPERO CRD420251266257

Chronic diseases like metabolic syndrome, autoimmune diseases, neurodegenerative pathologies, and cardiovascular diseases are caused by inflammation. Dietary interventions, especially omega-3 PUFAs, have been studied for their ability to regulate inflammation. The biological effects of omega-3 fatty acids, especially EPA and DHA, include absorption into cell membranes, modification of lipid mediators, and control of inflammatory signaling pathways. This review examines gene expression profiles and systemic and molecular indicators to determine omega-3 fatty acid supplementation's anti-inflammatory effects. Human clinical trials show that omega-3 supplementation reduces C-reactive protein (CRP), fibrinogen, and pro-inflammatory cytokines, depending on dose, EPA:DHA ratio, and baseline inflammatory status. Animal and in-vitro studies reveal pathways that modulate eicosanoid production, activate pro-resolving mediators, and suppress transcription factors like NF-κB. Omics studies show that epigenetic and transcriptomic changes mediate these effects. Quality evidence is presented, but limitations in study design, supplementation regimens, and biomarker selection weaken the conclusions. This study highlights data gaps, such as human gene expression data and inter-individual response variability and suggests future research. Overall, omega-3 supplementation may reduce inflammation and provide molecular insights for clinical and public health applications.

Motor impairments are common in children with autism spectrum disorder (ASD) and contribute to reduced functional independence, participation, and quality of life. Although motor-rehabilitation interventions can improve motor and adaptive outcomes, services are often fragmented, inconsistently delivered, and difficult to scale beyond single clinical settings. Multisite implementation of ASD motor-rehabilitation programs remains limited, underscoring the need for coordinated approaches that address both clinical and organizational challenges. This integrative narrative review synthesizes representative literature on motor-rehabilitation interventions for children with ASD alongside implementation-science and project-management frameworks relevant to multisite healthcare delivery in the United States. A broad search of peer-reviewed literature and policy sources published between 2000 and 2025 was conducted. Evidence was synthesized qualitatively with attention to implementation-relevant factors, governance structures, and scalability considerations; no quantitative synthesis or statistical analysis was performed. The reviewed literature indicates that motor-rehabilitation interventions can improve motor proficiency, adaptive behavior, and participation in children with ASD. However, the evidence base is dominated by small, single-site studies with substantial heterogeneity in intervention design and outcome reporting. Key barriers to multisite implementation include variability in workforce training, infrastructure, reimbursement models, data systems, and family engagement across settings. Implementation-science frameworks (e.g., the Consolidated Framework for Implementation Research (CFIR), Reach-Effectiveness-Adoption-Implementation-Maintenance (RE-AIM), and Normalization Process Theory) and project-management methodologies offer complementary strategies to address these barriers but are rarely integrated within ASD motor-rehabilitation research. Drawing on these domains, this review proposes a Coordinated Project-Management Framework to guide multisite implementation through iterative phases of initiation, planning, delivery, monitoring and evaluation, and sustainability. Scaling effective motor-rehabilitation services for children with ASD will require coordinated, multisite implementation rather than isolated clinic-based efforts. Future research should prioritize piloting and evaluating this framework in real-world healthcare networks using hybrid effectiveness-implementation designs to improve access, consistency, and equity in ASD motor rehabilitation.

INTRODUCTION: Condoms use is a unique method of contraception. It prevents both unplanned pregnancies and sexually transmitted infections. Unplanned pregnancy is a public health issue with clinical, economic, social, and psychological consequences, especially among adolescents. The effects of sexually transmitted infections including HIV/AIDS are diverse affecting reproductive health, and fertility, and are a stigma in society. The theory of planned behaviour is a theoretical framework that can be used to study the intention of condom use. it gives the relationship between major domains attitude, subjective norm, and perceived behavioural control with the intention. This study aimed to assess the intention to use condoms among adolescents in Pre-degree campus OAU Ile-Ife, using the theory of planned behaviour. METHODS: This study employed a descriptive cross-sectional design using a two-stage sampling technique among 360 adolescents in the Pre-degree campus Moro, Ile-Ife. A pretested self-administered questionnaire was used for data collection; the chi-square test and binary regression were done. RESULTS: Eighty-four percent (84%) of the respondents were yet to attain coitarche. Sixty-four (64%) of the respondents had no intention to use condoms. Only few (13%) consistently use condom. Respondents attitude (OR=1.81, 95%CI=1.05-3.13, p=0.033), and perceived behavioural control (OR=3.26, 95%CI=1.89-5.63, p=0.001) were predictors of intention to use condom. CONCLUSION: The study concluded that there is a relationship between domains of theory of planned behaviour and intention to use condom. There is need for development of health education intervention programs that focus on adolescents attitude and perceived behavioural to promote safer sexual practices.